OSLO, Norway, December 19, 2022 / B3C newswire / Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced that it has entered into a strategic manufacturing partnership with Richter-Helm BioLogi.
Published: May 12, 2021 By Alex Keown
Shanghai continues to be an area of focus for many pharmaceutical companies seeking a toehold in China. Companies like AstraZeneca, Novartis and others have opened offices in Shanghai. Two months ago, Germany’s Vetter, a contract development and manufacturing organization, opened offices there, and now, ITM AG, another Germany-based company is following suit. ITM AG established a subsidiary in Shanghai to accelerate introduction of its precision oncology portfolio in China.
The subsidiary will expand ITM’s growing operations in China, which is a key emerging market for novel radiomolecular precision oncology. The ITM Shanghai team will focus on expanding and accelerating access of targeted therapeutic and diagnostic radiopharmaceuticals for Chinese patients.
German CDMO Richter-Helm Triples cGMP Production Capacity to Accommodate Global Market Demand
HAMBURG, Germany, May 06, 2021 / B3C newswire / Richter-Helm BioLogics GmbH & Co. KG, a leading Germany-based, cGMP compliant biopharmaceutical Contract Development and Manufacturing Organization (CDMO) announced today the start of construction for an expansion project at its cGMP manufacturing facility in Bovenau, Germany. The new multi-product biological manufacturing facility is expected to begin full-scale operations and manufacturing by the end of 2023.
“The market for pharmaceutical biotechnology has been continuously growing and further growth is expected. In order to accommodate demand for high value biopharmaceutical products, Richter-Helm recently started expansion of its microbial manufacturing capacity and continues to push its overall growth strategy.”
INO-4800 COVID-19 Vaccine Description
INO-4800 is a DNA vaccine candidate matched to the novel coronavirus SARS-CoV-2, which causes the COVID-19 disease in humans.
INOVIO s INO-4800 is the only nucleic-acid-based vaccine stable at room temperature for more than a year and does not require frozen transport or for years of storage, which are important factors when implementing mass immunizations to battle the current pandemic, says INOVIO.
The INO-4800 vaccine contains the plasmid pGX9501, which encodes for the entire length of the Spike glycoprotein of SARS-CoV-2.
Inovio s proprietary platform hand-held smart device called CELLECTRA® leads the way forward for activation immunotherapy. CELLECTRA uses a brief electrical pulse to open small pores in the cell reversibly to allow the plasmids to enter.